{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T08:11:13Z","timestamp":1792743073702,"version":"4.5.0"},"reference-count":183,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003033","name":"Ministerio de Ciencia, Tecnolog\u00eda e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jpba.2024.116038","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T09:50:28Z","timestamp":1707990628000},"page":"116038","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Identification and quantification techniques of polymorphic forms - A review"],"prefix":"10.1016","volume":"242","author":[{"given":"Julian","family":"Ticona Chambi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinira","family":"Fandaruff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Lucia","family":"Cuffini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2024.116038_bib1","first-page":"1612","article-title":"The bioinequivalence of carbamazepine tablets with a history of clinical failures","volume":"9","author":"Meyer","year":"1992","journal-title":"Pharm. Res. . J. Am. Assoc. Pharm. Sci."},{"key":"10.1016\/j.jpba.2024.116038_bib2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0378-5173(89)90135-X","article-title":"Crystallisation of carbamazepine in tablets stored at elevated temperatures","volume":"50","author":"Matthews","year":"1989","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jpba.2024.116038_bib3","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/jps.2600560712","article-title":"Effect of polymorphism on the absorption of chloramphenicol from chloramphenicol palmitate","volume":"56","author":"Aguiar","year":"1967","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2024.116038_bib4","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1021\/op000023y","article-title":"Dealing with the impact of ritonavir polymorphs on the late stages of bulk drug process development","volume":"4","author":"Chemburkar","year":"2000","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.jpba.2024.116038_bib5","doi-asserted-by":"crossref","first-page":"5620","DOI":"10.1002\/chem.201103508","article-title":"Desmotropy, polymorphism, and solid-state proton transfer: four solid forms of an aromatic o-hydroxy schiff base","volume":"18","author":"Rub\u010di\u0107","year":"2012","journal-title":"Chem. - A Eur. J."},{"key":"10.1016\/j.jpba.2024.116038_bib6","unstructured":"The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit, Public statement: Suply of Norvir Hard Capsules, (1998). \u3008https:\/\/www.ema.europa.eu\/en\/news\/public-statement-supply-norvir-hard-capsules\u3009 (accessed April 27, 2021)."},{"key":"10.1016\/j.jpba.2024.116038_bib7","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3109\/03639049809085647","article-title":"Identification of the mebendazole polymorphic form present in raw materials and tablets available in South Africa","volume":"24","author":"Liebenberg","year":"1998","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jpba.2024.116038_bib8","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1517\/17425240802500870","article-title":"Crystallisation within transdermal rotigotine patch: Is there cause for concern","volume":"5","author":"Chaudhuri","year":"2008","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jpba.2024.116038_bib9","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.ejpb.2014.08.007","article-title":"Rotigotine: The first new chemical entity for transdermal drug delivery","volume":"88","author":"McAfee","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jpba.2024.116038_bib10","unstructured":"Food and Drug Administration (FDA), Important Recall Notice - Alertas Coumadin FDA, (2011). \u3008https:\/\/www.drgourmet.com\/warfarin\/recall.shtml\u3009 (accessed April 27, 2021)."},{"key":"10.1016\/j.jpba.2024.116038_bib11","unstructured":"CISION P.R. Neswwire, Additional Lots Added: Voluntary Nationwide Recall of 21 Lots of Piperacillin and Tazobactam for Injection, USP 40.5 grams due to Possibility of Precipitation \/ Crystallization in IV Bag or IV Line Upon Reconstitution, WESTON, FL, May 10, 2013 \/PRNewswire\/ - Apotex Corp. (2013). \u3008https:\/\/www.prnewswire.com\/news-releases\/additional-lots-added-voluntary-nationwide-recall-of-21-lots-of-piperacillin-and-tazobactam-for-injection-usp-405-grams-due-to-possibility-of-precipitation--crystallization-in-iv-bag-or-iv-line-upon-reconstitution\u3009- (accessed March 18, 2021)."},{"key":"10.1016\/j.jpba.2024.116038_bib12","unstructured":"P.W. Parker\/ Waichman LLP, 60 Million Avalide Tablets Recalled, NewsInfermo\/ PW Park. Waichman LLP. A Natl. Law Firm. (2010). \u3008https:\/\/www.yourlawyer.com\/newsinferno\/60-million-avalide-tablets-recalled\/\u3009 (accessed April 27, 2021)."},{"key":"10.1016\/j.jpba.2024.116038_bib13","unstructured":"World Health Organization - WHO, Polymorphism, in: The International Pharmacopoeia - Eleventh Edition, (2022). \u3008https:\/\/digicollections.net\/phint\/2022\/index.html#p\/home\u3009 (accessed March 14, 2023)."},{"key":"10.1016\/j.jpba.2024.116038_bib14","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1002\/jps.24148","article-title":"Limits of visual detection for finasteride polymorphs in prepared binary mixtures: analysis by X-ray powder diffraction","volume":"103","author":"Antonio","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2024.116038_bib15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev-chembioeng-061010-114224","article-title":"Crystal polymorphism in chemical process development","volume":"2","author":"Lee","year":"2011","journal-title":"Annu. Rev. Chem. Biomol. Eng."},{"key":"10.1016\/j.jpba.2024.116038_bib16","doi-asserted-by":"crossref","first-page":"18759","DOI":"10.3390\/molecules201018759","article-title":"Polymorph impact on the bioavailability and stability of poorly soluble drugs","volume":"20","author":"Censi","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.jpba.2024.116038_bib17","unstructured":"European Medicines Agency, Guideline on the chemistry of active substances (EMA\/454576\/2016), 2016."},{"key":"10.1016\/j.jpba.2024.116038_bib18","unstructured":"European Medicines Agency (EMA), ICH Topic Q 6 A - Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances (CPMP\/ICH\/367\/96), (2000)."},{"key":"10.1016\/j.jpba.2024.116038_bib19","unstructured":"Administraci\u00f3n Nacional de Medicamentos Alimentos y Tecnolog\u00eda M\u00e9dica (ANMAT), 1095. Polimorfismo, en: Farmacopea Argentina, Septima edici\u00f3n, (2003). \u3008https:\/\/www.argentina.gob.ar\/anmat\/farmacopea-argentina\/libro\u3009 (accessed March 14, 2023)."},{"key":"10.1016\/j.jpba.2024.116038_bib20","unstructured":"British Pharmacopoeia Commission, F. Polymorphism, in: British Pharmacopoeia, (2020) Appendix I F V-A181. \u3008https:\/\/www.webofpharma.com\/2022\/06\/british-pharmacopoeia-2022-bp-2022-pdf.html\u3009 (accessed March 14, 2023)."},{"key":"10.1016\/j.jpba.2024.116038_bib21","unstructured":"Council of Europe, 5.9 Polymorphism, in: European Pharmacopoeia 10.0, (2019). \u3008https:\/\/www.webofpharma.com\/2021\/03\/ep-10-european-pharmacopoeia-10th.html\u3009 (accessed March 14, 2023)."},{"key":"10.1016\/j.jpba.2024.116038_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123721","article-title":"Quantitative analysis and evaluation of solid-state stability of mebendazole Forms A and C suspensions by powder X-ray diffraction using the Rietveld method","volume":"650","author":"Ticona Chambi","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jpba.2024.116038_bib23","article-title":"Solid-state NMR-driven crystal structure prediction of molecular crystals: the case of mebendazole","volume":"28","author":"Bravetti","year":"2021","journal-title":"Chem. - A Eur. J."},{"key":"10.1016\/j.jpba.2024.116038_bib24","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ssnmr.2007.12.002","article-title":"A study in desmotropy","volume":"34","author":"Holzer","year":"2008","journal-title":"Solid State Nucl. Magn. Reson."},{"key":"10.1016\/j.jpba.2024.116038_bib25","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jpha.2019.07.001","article-title":"Irbesartan desmotropes: solid-state characterization, thermodynamic study and dissolution properties","volume":"9","author":"Araya-Sibaja","year":"2019","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.jpba.2024.116038_bib26","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10973-010-0817-6","article-title":"Techniques of differential scanning calorimetry for quantification of low contents of amorphous phases","volume":"102","author":"Lappalainen","year":"2010","journal-title":"J. Therm. Anal. Calorim."},{"key":"10.1016\/j.jpba.2024.116038_bib27","series-title":"Powder Diffraction Theory and Practice","author":"Dinnebier","year":"2008"},{"key":"10.1016\/j.jpba.2024.116038_bib28","unstructured":"V.K. Pecharsky, P.Y. Zavalij, Fundamentals of Powder Diffraction and Structural Characterization of Materials, 2nd ed., Springer Science & Business Media, New York, 2009."},{"key":"10.1016\/j.jpba.2024.116038_bib29","unstructured":"B.D. Cullity, Elements of x-ray diffraction, 2nd ed., Addison-Wesley, Indiana, 1977."},{"key":"10.1016\/j.jpba.2024.116038_bib30","unstructured":"H.G. Brittain, Polymorphism in Pharmaceutical Solids, 2nd ed., CRC Press, New York, 2009."},{"key":"10.1016\/j.jpba.2024.116038_bib31","first-page":"89","article-title":"Solid-state Characterization Techniques","author":"Newman","year":"2019","journal-title":": Pharm. Cryst."},{"key":"10.1016\/j.jpba.2024.116038_bib32","series-title":"Crystals","article-title":"Polymorphism in Molecular","author":"Bernstein","year":"2002"},{"key":"10.1016\/j.jpba.2024.116038_bib33","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1107\/S2052520616003954","article-title":"The Cambridge structural database","volume":"72","author":"Groom","year":"2016","journal-title":"Acta Crystallogr. Sect. B Struct. Sci. Cryst. Eng. Mater."},{"key":"10.1016\/j.jpba.2024.116038_bib34","unstructured":"G. Will, Powder Diffraction The Rietveld Method and the Two Stage Method to Determine and Refine Crystal Structures from Powder Diffraction Data, Springer Science & Business Media, 2016."},{"key":"10.1016\/j.jpba.2024.116038_bib35","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1107\/S0021889887086199","article-title":"Quantitative phase analysis from neutron powder diffraction data using the Rietveld method","volume":"20","author":"Hill","year":"1987","journal-title":"J. Appl. Crystallogr."},{"key":"10.1016\/j.jpba.2024.116038_bib36","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0731-7085(02)00053-5","article-title":"Quantitative analysis of mannitol polymorphs. X-ray powder diffractometry - exploring preferred orientation effects","volume":"28","author":"Campbell Roberts","year":"2001","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116038_bib37","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jpba.2012.01.013","article-title":"A comparative study of the use of powder X-ray diffraction, Raman and near infrared spectroscopy for quantification of binary polymorphic mixtures of piracetam","volume":"63","author":"Croker","year":"2012","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116038_bib38","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jpba.2008.11.033","article-title":"Quantitative determination of famotidine polymorphs: X-ray powder diffractometric and Raman spectrometric study","volume":"49","author":"N\u00e9met","year":"2008","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116038_bib39","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jpba.2015.01.005","article-title":"Quantification of febuxostat polymorphs using powder X-ray diffraction technique","volume":"107","author":"bo Qiu","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116038_bib40","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1107\/S0021889886089458","article-title":"Correction of intensities of preferred orientation in powder diffractometry: application of the march model","volume":"19","author":"Dollase","year":"1986","journal-title":"J. Appl. Crystallogr."},{"key":"10.1016\/j.jpba.2024.116038_bib41","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1107\/S0021889893001219","article-title":"Application of symmetrized harmonics expansion to correction of the preferred orientation effect","volume":"26","author":"Jarvinen","year":"1993","journal-title":"J. Appl. Crystallogr."},{"key":"10.1016\/j.jpba.2024.116038_bib42","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1107\/S0021889808041149","article-title":"Spherical harmonics preferential orientation corrections and structure solution from powder diffraction data - a possible avenue of last resort","volume":"42","author":"Whitfield","year":"2009","journal-title":"J. Appl. Crystallogr."},{"key":"10.1016\/j.jpba.2024.116038_bib43","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1107\/S002188980001623X","article-title":"Alternative algorithm for the correction of preferred orientation in Rietveld analysis","volume":"34","author":"Bergmann","year":"2001","journal-title":"J. Appl. Crystallogr."},{"key":"10.1016\/j.jpba.2024.116038_bib44","unstructured":"Brazilian Health Regulatory Agency, \u30085.2.31\u3009X-ray diffraction by, in: Brazilian Pharmacopoeia, 6th edition, (2019) MG5.2.31-00. \u3008https:\/\/www.gov.br\/anvisa\/pt-br\/english\/pharmacopeia\u3009 (accessed January 5, 2024)."},{"key":"10.1016\/j.jpba.2024.116038_bib45","unstructured":"British Pharmacopoeia Commission, Characterization of crystalline and partially crystalline solids by X-ray powder diffraction (XRPD), in: British Pharmacopoeia, (2020) Appendix XVII Q V-A589. \u3008https:\/\/www.webofpharma.com\/2022\/06\/british-pharmacopoeia-2022-bp-2022-pdf.html\u3009 (accessed March 14, 2023)."},{"key":"10.1016\/j.jpba.2024.116038_bib46","first-page":"379","article-title":"Characterization of crystalline and partially crystalline solids by X-ray powder diffraction (XRPD)","volume":"10.0","author":"Council of Europe","year":"2019","journal-title":"Eur. Pharm."},{"key":"10.1016\/j.jpba.2024.116038_bib47","unstructured":"The Minister of Health Labour and Welfare, 2.58 X-Ray Powder Diffraction Method in: Japanese Pharmacopoeia XVII, (2021) 82\u201386."},{"key":"10.1016\/j.jpba.2024.116038_bib48","unstructured":"United States Pharmacopeial Convention (USP), \u3008941\u3009Characterization of crystalline and partially crystalline solids BY X-ray powder diffraction (XRPD), in: United State Pharmacopeia National Formulary - USP 44 - NF 39, (2021) (941). \u3008https:\/\/www.webofpharma.com\/2022\/01\/usp-2021-united-state-pharmacopeia-44.html\u3009\u3008\u3009(accessed March 14, 2023)."},{"key":"10.1016\/j.jpba.2024.116038_bib49","unstructured":"Secretaria de Salud - M\u00e9xico (FM-FEUM), MGA 0231. Prueba de Cristalinidade in: Farmacopea de los Estados Unidos Mexicanos 13.0, (2021) 306\u2013312."},{"key":"10.1016\/j.jpba.2024.116038_bib50","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1002\/jps.22482","article-title":"Quantitative phase analyses through the rietveld method with X-ray powder diffraction data of heat-treated carbamazepine form III","volume":"100","author":"Antonio","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2024.116038_bib51","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0731-7085(96)01796-7","article-title":"Quantitation of cefepime \u00b7 2HCl dihydrate in cefepime \u00b7 2HCl monohydrate by diffuse reflectance IR and powder X-ray diffraction techniques","volume":"15","author":"Bugay","year":"1996","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116038_bib52","first-page":"15","article-title":"Quantification of clarithromycin polymorphs in presence of tablet excipients","volume":"5","author":"Kuncham","year":"2014","journal-title":"J. Excip. Food Chem."},{"key":"10.1016\/j.jpba.2024.116038_bib53","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jtusci.2015.03.011","article-title":"Identification and quantitative determination of eletriptan hydrobromide polymorphs: Thermal, diffractometric and spectrometric studies","volume":"9","author":"Kommavarapu","year":"2015","journal-title":"J. Taibah Univ. Sci."},{"key":"10.1016\/j.jpba.2024.116038_bib54","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jpba.2018.05.026","article-title":"Quantitation of polymorphic impurity in entecavir polymorphic mixtures using powder X-ray diffractometry and Raman spectroscopy","volume":"158","author":"Kang","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116038_bib55","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jpba.2011.05.038","article-title":"Potential of synchrotron X-ray powder diffractometry for detection and quantification of small amounts of crystalline drug substances in pharmaceutical tablets","volume":"56","author":"Yamada","year":"2011","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116038_bib56","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jpba.2017.07.048","article-title":"Quantification of gabapentin polymorphs in gabapentin\/excipient mixtures using solid state 13C NMR spectroscopy and X-ray powder diffraction","volume":"146","author":"Tinmanee","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116038_bib57","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1017\/S0885715615000226","article-title":"Characterization of hydrochlorothiazide in solid formulations","volume":"30","author":"De Salvi","year":"2015","journal-title":"Powder Diffr."},{"key":"10.1016\/j.jpba.2024.116038_bib58","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jpba.2015.06.011","article-title":"Journal of Pharmaceutical and biomedical analysis quantitative determination of two polymorphic forms of imatinib mesylate in a drug substance and tablet formulation by X-ray powder diffraction, differential scanning calorimetry and attenuated total refl","volume":"114","author":"Atici","year":"2015","journal-title":"J. Pharm. Biomed. Anal. J."},{"key":"10.1016\/j.jpba.2024.116038_bib59","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/jps.20320","article-title":"A novel standard sample powder preparation method for quantitative analysis of polymorphs","volume":"94","author":"Okumura","year":"2005","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2024.116038_bib60","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1002\/jps.21142","article-title":"A quick method for the quantitative analysis of mixtures. 1. Powder X-ray diffraction","volume":"97","author":"Dong","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2024.116038_bib61","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/jaoacint\/qsaa166","article-title":"Quantification of losartan potassium polymorphs using powder X-ray diffraction","volume":"104","author":"Lou","year":"2021","journal-title":"J. AOAC Int."},{"key":"10.1016\/j.jpba.2024.116038_bib62","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jpba.2013.08.035","article-title":"Phase quantification of antihypertensive drugs - chlorthalidone, hydrochlorothiazide, losartan and combinations, losartan\/chlorthalidone and losartan\/hydrochlorothiazide - by the rietveld method","volume":"88","author":"Reis do Carmo","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116038_bib63","first-page":"1760","article-title":"Rietveld method in the analysis of polymorphism in mebendazole tablets acquired in Brazil\u2019s drugstores","volume":"26","author":"Salvi","year":"2015","journal-title":"J. Braz. Chem. Soc."},{"key":"10.1016\/j.jpba.2024.116038_bib64","first-page":"2271","article-title":"Characterization of polymorph transformations that decrease the stability of tablets containing the WHO essential drug mebendazole","volume":"101","author":"Brits","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2024.116038_bib65","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jpba.2005.01.025","article-title":"Variable-temperature X-ray powder diffraction analysis of the crystal transformation of the pharmaceutically preferred polymorph C of mebendazole","volume":"38","author":"De Villiers","year":"2005","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116038_bib66","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jpba.2006.08.030","article-title":"Quantification of olanzapine polymorphs using powder X-ray diffraction technique","volume":"43","author":"Tiwari","year":"2007","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116038_bib67","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ijpharm.2008.08.049","article-title":"Quantitative determination of polymorphic impurity by X-ray powder diffractometry in an OROS\u00ae formulation","volume":"366","author":"Varasteh","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jpba.2024.116038_bib68","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejps.2019.01.014","article-title":"Quantifying API polymorphs in formulations using X-ray powder diffraction and multivariate standard addition method combined with net analyte signal analysis","volume":"130","author":"Zappi","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2024.116038_bib69","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jpba.2008.09.054","article-title":"Quantitative solid-state analysis of three solid forms of ranitidine hydrochloride in ternary mixtures using Raman spectroscopy and X-ray powder diffraction","volume":"49","author":"Chieng","year":"2009","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116038_bib70","doi-asserted-by":"crossref","first-page":"283","DOI":"10.4236\/pp.2013.43041","article-title":"Quantifying isotibolone in raw materials of tibolone","volume":"04","author":"Antonio","year":"2013","journal-title":"Pharmacol.\u00a0Pharm."},{"key":"10.1016\/j.jpba.2024.116038_bib71","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ijpharm.2011.05.058","article-title":"Quantification of polymorphic impurity in an enantiotropic polymorph system using differential scanning calorimetry, X-ray powder diffraction and Raman spectroscopy","volume":"415","author":"Li","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jpba.2024.116038_bib72","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.talanta.2013.09.006","article-title":"Solid-state evaluation and polymorphic quantification of venlafaxine hydrochloride raw materials using the Rietveld method","volume":"117","author":"Bernardi","year":"2013","journal-title":"Talanta"},{"key":"10.1016\/j.jpba.2024.116038_bib73","doi-asserted-by":"crossref","first-page":"15341","DOI":"10.1021\/acs.analchem.2c02828","article-title":"Quantifying micromolar crystallinity in pharmaceutical materials utilizing 19F solid-state NMR","volume":"94","author":"Du","year":"2022","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2024.116038_bib74","unstructured":"S.R. Byrn, R.R. Pfeiffer, J.G. Stowell, Solid-State Chemistry of Drugs, 2nd ed., SSCI Inc, West Lafayette, Indiana, 1999."},{"key":"10.1016\/j.jpba.2024.116038_bib75","doi-asserted-by":"crossref","unstructured":"R. Hilfiker, M. Von Raumer, Polymorphism in the Pharmaceutical Industry, Wiley-VCH, Weinheim, Germany, 2019.","DOI":"10.1002\/9783527697847"},{"key":"10.1016\/j.jpba.2024.116038_bib76","series-title":"Therm. Anal. Pharm.","first-page":"1","article-title":"Principles of Differential Scanning Calorimetry","author":"Reading","year":"2006"},{"key":"10.1016\/j.jpba.2024.116038_bib77","doi-asserted-by":"crossref","unstructured":"R.A. Storey, I. Ym\u00e9n, Solid State Characterization of Pharmaceuticals, John Wiley & Sons, Ltd, Chichester, UK, 2011.","DOI":"10.1002\/9780470656792"},{"key":"10.1016\/j.jpba.2024.116038_bib78","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1023\/B:JTAN.0000042151.60566.0f","article-title":"Utilization of DSC for pharmaceutical crystal form quantitation","volume":"78","author":"Vitez","year":"2004","journal-title":"J. Therm. Anal. Calorim."},{"key":"10.1016\/j.jpba.2024.116038_bib79","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijpharm.2004.01.018","article-title":"The potential of high speed DSC (Hyper-DSC) for the detection and quantification of small amounts of amorphous content in predominantly crystalline samples","volume":"274","author":"Saunders","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jpba.2024.116038_bib80","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.powtec.2006.05.019","article-title":"The comparison of seven different methods to quantify the amorphous content of spray dried lactose","volume":"167","author":"Lehto","year":"2006","journal-title":"Powder Technol."},{"key":"10.1016\/j.jpba.2024.116038_bib81","unstructured":"Administraci\u00f3n Nacional de Medicamentos Alimentos y Tecnolog\u00eda M\u00e9dica (ANMAT), \u300820\u3009An\u00e1lisis T\u00e9rmico, en: Farmacopea Argentina, Septima edici\u00f3n, (2003). \u3008https:\/\/www.argentina.gob.ar\/anmat\/farmacopea-argentina\/libro\u3009 (accessed March 14, 2023)."},{"key":"10.1016\/j.jpba.2024.116038_bib82","unstructured":"Brazilian Health Regulatory Agency, \u30085.2.27\u3009 Thermal analysis, in: Brazilian Pharmacopoeia, 6th edition, (2019) MG5.2.27-00. \u3008https:\/\/www.gov.br\/anvisa\/pt-br\/english\/pharmacopeia\u3009 (accessed January 5, 2024)."},{"key":"10.1016\/j.jpba.2024.116038_bib83","unstructured":"British Pharmacopoeia Commission, Thermal Analysis, in: British Pharmacopoeia, (2020) Appendix V M V-A282. \u3008https:\/\/www.webofpharma.com\/2022\/06\/british-pharmacopoeia-2022-bp-2022-pdf.html\u3009 (accessed March 14, 2023)."},{"key":"10.1016\/j.jpba.2024.116038_bib84","unstructured":"Council of Europe, \u30082.2.34\u3009Thermal Analysis, in: European Pharmacopoeia 10.0, (2019) 61\u201363. \u3008https:\/\/www.webofpharma.com\/2021\/03\/ep-10-european-pharmacopoeia-10th.html\u3009 (accessed March 14, 2023)."},{"key":"10.1016\/j.jpba.2024.116038_bib85","unstructured":"The Minister of Health Labour and Welfare, 2.52 Thermal Analysis in: Japanese Pharmacopoeia XVII, (2021) 72\u201375."},{"key":"10.1016\/j.jpba.2024.116038_bib86","unstructured":"Secretaria de Salud - M\u00e9xico (FM-FEUM), MGA 0089. An\u00e1lisis T\u00e9rmicos in: Farmacopea de los Estados Unidos Mexicanos 13.0, (2021) 268\u2013274."},{"key":"10.1016\/j.jpba.2024.116038_bib87","unstructured":"United States Pharmacopeial Convention, \u3008891\u3009 Thermal Analysis, in: United State Pharmacopeia National Formulary - USP 44 - NF 39, (2021). \u3008https:\/\/www.webofpharma.com\/2022\/01\/usp-2021-united-state-pharmacopeia-44.html\u3009\u3008\u3009(accessed March 14, 2023)."},{"key":"10.1016\/j.jpba.2024.116038_bib88","series-title":"J. Therm. Anal. Calorim.","article-title":"Polymorphic quantification of dexketoprofen trometamol by differential scanning calorimetry","author":"Bruni","year":"2022"},{"key":"10.1016\/j.jpba.2024.116038_bib89","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jpba.2012.06.029","article-title":"Polymorphism in nimodipine raw materials: development and validation of a quantitative method through differential scanning calorimetry","volume":"70","author":"Riekes","year":"2012","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116038_bib90","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ijpharm.2007.08.015","article-title":"The use of high-speed differential scanning calorimetry (Hyper-DSC\u2122) in the study of pharmaceutical polymorphs","volume":"350","author":"McGregor","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jpba.2024.116038_bib91","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.tca.2003.09.031","article-title":"The use of high-speed differential scanning calorimetry (Hyper-DSC\u2122) to study the thermal properties of carbamazepine polymorphs","volume":"417","author":"McGregor","year":"2004","journal-title":"Thermochim. Acta"},{"key":"10.1016\/j.jpba.2024.116038_bib92","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1023\/A:1025758127358","article-title":"Thermal analysis of trace levels of polymorphic impurity in salmeterol xinafoate samples","volume":"20","author":"Tong","year":"2003","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jpba.2024.116038_bib93","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ijpharm.2005.02.024","article-title":"An improved thermoanalytical approach to quantifying trace levels of polymorphic impurity in drug powders","volume":"295","author":"Tong","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jpba.2024.116038_bib94","unstructured":"The British Pharmacopoeia Commission, Nuclear Magnetic Resonance Spectrometry, in: British Pharmacopoeia, (2020) Appendix II C V-A192. \u3008https:\/\/www.webofpharma.com\/2022\/06\/british-pharmacopoeia-2022-bp-2022-pdf.html\u3009 (accessed March 14, 2023)."},{"key":"10.1016\/j.jpba.2024.116038_bib95","doi-asserted-by":"crossref","unstructured":"G. Gauglitz, D.S. Moore, Handbook of Spectroscopy, 2nd ed., Wiley-VCH, 2014.","DOI":"10.1002\/9783527654703"},{"key":"10.1016\/j.jpba.2024.116038_bib96","unstructured":"B.H. Stuart, Front Matter, in: Anal. Tech. Sci., John Wiley & Sons, 2005: pp. i\u2013xvi."},{"key":"10.1016\/j.jpba.2024.116038_bib97","unstructured":"Brazilian Health Regulatory Agency, \u30085.2.14\u3009Spectrophotometry in ultraviolet, visible and infrared, in: Brazilian Pharmacopoeia, 6th edition, (2019) MG5.2.14-00. \u3008https:\/\/www.gov.br\/anvisa\/pt-br\/english\/pharmacopeia\u3009 (accessed January 5, 2024)."},{"key":"10.1016\/j.jpba.2024.116038_bib98","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jpba.2012.10.002","article-title":"Quantitative polymorph contaminant analysis in tablets using Raman and near infra-red spectroscopies","volume":"72","author":"Hennigan","year":"2012","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116038_bib99","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1211\/jpp.59.2.0005","article-title":"Raman spectroscopy for quantitative analysis of pharmaceutical solids","volume":"59","author":"Strachan","year":"2007","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jpba.2024.116038_bib100","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jpba.2017.06.017","article-title":"Characterization of pharmaceutically relevant materials at the solid state employing chemometrics methods","volume":"147","author":"Calvo","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116038_bib101","unstructured":"Council of Europe, \u30082.2.24\u3009Absorption Spectrosphotometry Infrared, in: European Pharmacopoeia 10.0, (2019) 39\u201342. \u3008https:\/\/www.webofpharma.com\/2021\/03\/ep-10-european-pharmacopoeia-10th.html\u3009 (accessed March 14, 2023)."},{"key":"10.1016\/j.jpba.2024.116038_bib102","unstructured":"British Pharmacopoeia Commission, Infrared Spectrophotometry, in: British Pharmacopoeia, (2020) Appendix II A V-A182. \u3008https:\/\/www.webofpharma.com\/2022\/06\/british-pharmacopoeia-2022-bp-2022-pdf.html\u3009 (accessed March 14, 2023)."},{"key":"10.1016\/j.jpba.2024.116038_bib103","unstructured":"Administraci\u00f3n Nacional de Medicamentos Alimentos y Tecnolog\u00eda M\u00e9dica (ANMAT), \u3008460\u3009Espectrofotometria Infraroja, en: Farmacopea Argentina, Septima edici\u00f3n, (2003). \u3008https:\/\/www.argentina.gob.ar\/anmat\/farmacopea-argentina\/libro\u3009 (accessed March 14, 2023)."},{"key":"10.1016\/j.jpba.2024.116038_bib104","unstructured":"World Health Organization - WHO, \u30081.7\u3009Spectrophotometry in the infrared region, in: The International Pharmacopoeia - Eleventh Edition, (2022) 2014\u201301. \u3008https:\/\/digicollections.net\/phint\/2022\/index.html#p\/home\u3009 (accessed March 14, 2023)."},{"key":"10.1016\/j.jpba.2024.116038_bib105","unstructured":"The Minister of Health Labour and Welfare, 2.25 Infrared Spectrophotometry in: Japanese Pharmacopoeia XVII, (2021) 53\u201354."},{"key":"10.1016\/j.jpba.2024.116038_bib106","unstructured":"Secretaria de Salud - M\u00e9xico (FM-FEUM), MGA 0351. Espectrofotometr\u00eda Infrarroja in: Farmacopea de los Estados Unidos Mexicanos 13.0, (2021) 381\u2013387."},{"key":"10.1016\/j.jpba.2024.116038_bib107","unstructured":"United States Pharmacopeial Convention, \u3008197\u3009 Spectroscopic Identification Tests, in: United State Pharmacopeia National Formulary - USP 44 - NF 39, (2021). \u3008https:\/\/www.webofpharma.com\/2022\/01\/usp-2021-united-state-pharmacopeia-44.html\u3009\u3008\u3009(accessed March 14, 2023)."},{"key":"10.1016\/j.jpba.2024.116038_bib108","unstructured":"Council of Europe, 2.2.40 Near-Infrared spectroscopy, in: European Pharmacopoeia 10.0, (2019) 70\u201375. \u3008https:\/\/www.webofpharma.com\/2021\/03\/ep-10-european-pharmacopoeia-10th.html\u3009 (accessed March 14, 2023)."},{"key":"10.1016\/j.jpba.2024.116038_bib109","unstructured":"United States Pharmacopeial Convention (USP), \u30081856\u3009 Near-Infrared Spectroscopy\u2014Theory and Practice, in: United State Pharmacopeia National Formulary - USP 44 - NF 39, (2021). \u3008https:\/\/www.webofpharma.com\/2022\/01\/usp\u3009 (accessed March 14, 2023)."},{"key":"10.1016\/j.jpba.2024.116038_bib110","unstructured":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA), Espectrofotometria no Ultravioleta, Vis\u00edvel e Infravermelho, em: Farmacopeia Brasileira, 6a edi\u00e7\u00e3o, 1 (2019) 124\u2013130. \u3008https:\/\/www.gov.br\/anvisa\/pt-br\/english\/pharmacopeia\u3009 (accessed March 14, 2023)."},{"key":"10.1016\/j.jpba.2024.116038_bib111","unstructured":"Council of Europe (EP-CoE), Near-infrared spectroscopy, in: Eur. Pharmacopoeia 8.0, 2013: pp. 38\u201367."},{"key":"10.1016\/j.jpba.2024.116038_bib112","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0731-7085(01)00343-0","article-title":"A simple quantitative FT-IR approach for the study of a polymorphic transformation under crystallization slurry conditions","volume":"25","author":"Skrdla","year":"2000","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116038_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.saa.2021.120354","article-title":"Form quantitation in desmotropic mixtures of albendazole bulk drug by chemometrics-assisted analysis of vibrational spectra","volume":"265","author":"Moroni","year":"2022","journal-title":"Spectrochim. Acta - Part A Mol. Biomol. Spectrosc."},{"key":"10.1016\/j.jpba.2024.116038_bib114","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1177\/0003702820905367","article-title":"A comparative approach to screen the capability of Raman and infrared (mid- and near-) spectroscopy for quantification of low-active pharmaceutical ingredient content solid dosage forms: the case of alprazolam","volume":"74","author":"Makraduli","year":"2020","journal-title":"Appl. Spectrosc."},{"key":"10.1016\/j.jpba.2024.116038_bib115","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jpba.2016.03.003","article-title":"Semi-quantitative prediction of a multiple API solid dosage form with a combination of vibrational spectroscopy methods","volume":"124","author":"Hertrampf","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116038_bib116","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.chemolab.2014.02.004","article-title":"Quantification of the enantiomeric excess of two APIs by means of near infrared spectroscopy and chemometrics","volume":"133","author":"Rigoni","year":"2014","journal-title":"Chemom. Intell. Lab. Syst."},{"key":"10.1016\/j.jpba.2024.116038_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.113922","article-title":"Classification of polymorphic forms of fluconazole in pharmaceuticals by FT-IR and FT-NIR spectroscopy","volume":"196","author":"Alaoui Mansouri","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116038_bib118","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jpba.2017.02.053","article-title":"Quantitative analysis of binary polymorphs mixtures of fusidic acid by diffuse reflectance FTIR spectroscopy, diffuse reflectance FT-NIR spectroscopy, Raman spectroscopy and multivariate calibration","volume":"140","author":"Guo","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116038_bib119","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0378-5173(97)00378-5","article-title":"Application of attenuated total reflectance FTIR spectroscopy to the analysis of mixtures of pharmaceutical polymorphs","volume":"163","author":"Salari","year":"1998","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jpba.2024.116038_bib120","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jpba.2004.10.016","article-title":"Implementation of a simple semi-quantitative near-infrared method for the classification of clinical trial tablets","volume":"37","author":"De Maesschalck","year":"2005","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116038_bib121","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jpba.2013.11.011","article-title":"Low level drug product API form analysis - Avalide tablet NIR quantitative method development and robustness challenges","volume":"89","author":"Pan","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116038_bib122","doi-asserted-by":"crossref","first-page":"5318","DOI":"10.1002\/jps.21373","article-title":"Analysis of low content drug tablets by transmission near infrared spectroscopy: selection of calibration ranges according to multivariate detection and quantitation limits of PLS models","volume":"97","author":"Alcal\u00e0","year":"2008","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.jpba.2024.116038_bib123","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1208\/pt070129","article-title":"Quantitation of drug content in a low dosage formulation by transmission near infrared spectroscopy","volume":"7","author":"Meza","year":"2006","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jpba.2024.116038_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113766","article-title":"Calibration transfer between modelled and commercial pharmaceutical tablet for API quantification using backscattering NIR, Raman and transmission Raman spectroscopy (TRS)","volume":"194","author":"Wang","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116038_bib125","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jpba.2016.01.035","article-title":"Mebendazole crystal forms in tablet formulations. An ATR-FTIR\/chemometrics approach to polymorph assignment","volume":"122","author":"Calvo","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116038_bib126","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.jpba.2015.08.018","article-title":"Quantitative analysis of mebendazole polymorphs in pharmaceutical raw materials using near-infrared spectroscopy","volume":"115","author":"Da Silva","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116038_bib127","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jpba.2009.09.001","article-title":"Simultaneous quantitative analysis of mebendazole polymorphs A-C in powder mixtures by DRIFTS spectroscopy and ANN modeling","volume":"51","author":"Kachrimanis","year":"2009","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116038_bib128","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/jrs.1952","article-title":"Polymorphism incidence in commercial tablets of mebendazole: a vibrational spectroscopy investigation","volume":"39","author":"Ayala","year":"2008","journal-title":"J. Raman Spectrosc."},{"key":"10.1016\/j.jpba.2024.116038_bib129","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ijpharm.2008.04.039","article-title":"Analysing the crystal purity of mebendazole raw material and its stability in a suspension formulation","volume":"361","author":"Agatonovic-Kustrin","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jpba.2024.116038_bib130","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/bip.10041","article-title":"Analysis of mebendazole polymorphs by Fourier transform IR spectrometry using chemometric methods","volume":"67","author":"Aboul-Enein","year":"2001","journal-title":"Biopolymers"},{"key":"10.1016\/j.jpba.2024.116038_bib131","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.saa.2015.01.036","article-title":"A rapid Fourier-transform infrared (FTIR) spectroscopic method for direct quantification of paracetamol content in solid pharmaceutical formulations","volume":"141","author":"Mallah","year":"2015","journal-title":"Spectrochim. Acta - Part A Mol. Biomol. Spectrosc."},{"key":"10.1016\/j.jpba.2024.116038_bib132","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1208\/s12249-007-9003-y","article-title":"Use of drifts and PLS for the determination of polymorphs of piroxicam alone and in combination with pharmaceutical excipients: A technical note","volume":"9","author":"Tantishaiyakul","year":"2008","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jpba.2024.116038_bib133","doi-asserted-by":"crossref","DOI":"10.1016\/j.vibspec.2023.103625","article-title":"Quantitative analysis of pyrazinamide polymorphs in ternary mixtures by ATR-FTIR and Raman spectroscopy with multivariate calibration","volume":"130","author":"Zhou","year":"2024","journal-title":"Vib. Spectrosc."},{"key":"10.1016\/j.jpba.2024.116038_bib134","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jpba.2017.04.048","article-title":"Quantification of active ingredients in semi-solid pharmaceutical formulations by near infrared spectroscopy","volume":"142","author":"Schlegel","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116038_bib135","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jpba.2010.05.002","article-title":"Quantitative analysis of sulfathiazole polymorphs in ternary mixtures by attenuated total reflectance infrared, near-infrared and Raman spectroscopy","volume":"53","author":"Hu","year":"2010","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116038_bib136","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/1520-6017(200103)90:3<360::AID-JPS11>3.0.CO;2-U","article-title":"Low-level determination of polymorph composition in physical mixtures by near-infrared reflectance spectroscopy","volume":"90","author":"Patel","year":"2001","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2024.116038_bib137","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.xphs.2015.11.007","article-title":"Spectroscopic-based chemometric models for quantifying low levels of solid-state transitions in extended release theophylline formulations","volume":"105","author":"Korang-Yeboah","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2024.116038_bib138","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jpba.2008.05.007","article-title":"Tablet identification using near-infrared spectroscopy (NIRS) for pharmaceutical quality control","volume":"48","author":"Alvarenga","year":"2008","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116038_bib139","doi-asserted-by":"crossref","unstructured":"H. Kuzmany, Solid-State Spectroscopy - An introduction, 2nd ed., Springer, 2009.","DOI":"10.1007\/978-3-642-01479-6"},{"key":"10.1016\/j.jpba.2024.116038_bib140","unstructured":"S. Sasic, Pharmaceutical Applications of Raman Spectroscopy, John Wiley & Sons, Sandwich, UK, 2008."},{"key":"10.1016\/j.jpba.2024.116038_bib141","unstructured":"United States Pharmacopeial Convention, \u30081858\u3009 Raman Spectroscopy\u2014Theory and Practice, in: United State Pharmacopeia National Formulary - USP 44 - NF 39, (2021). \u3008https:\/\/www.webofpharma.com\/2022\/01\/usp-2021-united-state-pharmacopeia-44.html\u3009\u3008\u3009(accessed March 14, 2023)."},{"key":"10.1016\/j.jpba.2024.116038_bib142","doi-asserted-by":"crossref","first-page":"6894","DOI":"10.1021\/acs.analchem.9b01269","article-title":"Detecting and Quantifying Microscale Chemical Reactions in Pharmaceutical Tablets by Stimulated Raman Scattering Microscopy","author":"Figueroa","year":"2019","journal-title":"Anal. Chem."},{"issue":"322","key":"10.1016\/j.jpba.2024.116038_bib143","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1126\/science.1165758","article-title":"Label-free biomedical imaging with high sensitivity by stimulated Raman scattering microscopy","volume":"80","author":"Freudiger","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.jpba.2024.116038_bib144","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1039\/C5CS00693G","article-title":"Stimulated Raman scattering microscopy: An emerging tool for drug discovery","volume":"45","author":"Tipping","year":"2016","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jpba.2024.116038_bib145","unstructured":"The British Pharmacopoeia Commission, Raman Spectroscopy, in: British Pharmacopoeia, (2020) Appendix II H V-A206. \u3008https:\/\/www.webofpharma.com\/2022\/06\/british-pharmacopoeia-2022-bp-2022-pdf.html\u3009 (accessed March 14, 2023)."},{"key":"10.1016\/j.jpba.2024.116038_bib146","unstructured":"Council of Europe, \u30082.2.48\u3009Raman Spectroscopy, in: European Pharmacopoeia 10.0, (2019). \u3008https:\/\/www.webofpharma.com\/2021\/03\/ep-10-european-pharmacopoeia-10th.html\u3009 (accessed March 14, 2023)."},{"key":"10.1016\/j.jpba.2024.116038_bib147","unstructured":"The Minister of Health Labour and Welfare, 2.26 Raman Spectroscopy in: Japanese Pharmacopoeia XVII, (2021) 54\u201356."},{"key":"10.1016\/j.jpba.2024.116038_bib148","unstructured":"Secretaria de Salud - M\u00e9xico (FM-FEUM), MGA 0336. Espectroscopia Raman in: Farmacopea de los Estados Unidos Mexicanos 13.0, (2021) 374\u2013379."},{"key":"10.1016\/j.jpba.2024.116038_bib149","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1021\/acs.analchem.8b04365","article-title":"Transmission low-frequency Raman spectroscopy for quantification of crystalline polymorphs in pharmaceutical tablets","volume":"91","author":"Inoue","year":"2019","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2024.116038_bib150","doi-asserted-by":"crossref","first-page":"14128","DOI":"10.3390\/molecules190914128","article-title":"Simultaneous quantification of three polymorphic forms of carbamazepine in the presence of excipients using raman spectroscopy","volume":"19","author":"Farias","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.jpba.2024.116038_bib151","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.xphs.2022.09.009","article-title":"Quantitative monitoring of cocrystal polymorphisms in model tablets using transmission low-frequency Raman spectroscopy","volume":"112","author":"Inoue","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2024.116038_bib152","article-title":"Solid-state quantification of cocrystals in pharmaceutical tablets using transmission low-frequency Raman spectroscopy","author":"Inoue","year":"2019","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2024.116038_bib153","doi-asserted-by":"crossref","DOI":"10.1016\/j.saa.2020.118446","article-title":"Quantitative analysis of solid dosage forms of cefixime using Raman spectroscopy","volume":"238","author":"Bajwa","year":"2020","journal-title":"Spectrochim. Acta - Part A Mol. Biomol. Spectrosc."},{"key":"10.1016\/j.jpba.2024.116038_bib154","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.molstruc.2005.10.012","article-title":"Solid state characterization of chloramphenicol palmitate. Raman spectroscopy applied to pharmaceutical polymorphs","volume":"785","author":"Gamberini","year":"2006","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.jpba.2024.116038_bib155","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jpba.2018.05.010","article-title":"Comparison of macro and micro Raman measurement for reliable quantitative analysis of pharmaceutical polymorphs","volume":"157","author":"Paiva","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116038_bib156","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.xphs.2016.10.014","article-title":"Dispersive Raman spectroscopy for quantifying amorphous drug content in intact tablets","volume":"106","author":"Wabuyele","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2024.116038_bib157","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1366\/000370207782597085","article-title":"Quantitative transmission raman spectroscopy of pharmaceutical tablets and capsules","volume":"61","author":"Johansson","year":"2007","journal-title":"Appl. Spectrosc."},{"key":"10.1016\/j.jpba.2024.116038_bib158","doi-asserted-by":"crossref","DOI":"10.1016\/j.saa.2020.118900","article-title":"Raman spectroscopy for the qualitative and quantitative analysis of solid dosage forms of Sitagliptin","volume":"245","author":"Bakkar","year":"2021","journal-title":"Spectrochim. Acta - Part A Mol. Biomol. Spectrosc."},{"key":"10.1016\/j.jpba.2024.116038_bib159","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jpba.2018.04.008","article-title":"Quantifying low levels (<0.5% w\/w) of warfarin sodium salts in oral solid dose forms using Transmission Raman spectroscopy","volume":"155","author":"Griffen","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116038_bib160","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/jps.24524","article-title":"Chemometric model development and comparison of Raman and 13C solid-state nuclear magnetic resonance-chemometric methods for quantification of crystalline\/amorphous warfarin sodium fraction in the formulations","volume":"104","author":"Rahman","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2024.116038_bib161","unstructured":"D.L. Pavia, G.M. Lampman, G.S. Kriz, J.R. Vyvyan, Introduction to Spectroscopy, 5th ed., Cengage Learning, Stamford, 2015."},{"key":"10.1016\/j.jpba.2024.116038_bib162","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1080\/05704920801944338","article-title":"Solid-state NMR studies of pharmaceutical systems","volume":"43","author":"Geppi","year":"2008","journal-title":"Appl. Spectrosc. Rev."},{"key":"10.1016\/j.jpba.2024.116038_bib163","article-title":"Solid-state NMR spectroscopy","volume":"1","author":"Reif","year":"2021","journal-title":"Nat. Rev. Methods Prim."},{"key":"10.1016\/j.jpba.2024.116038_bib164","doi-asserted-by":"crossref","DOI":"10.1016\/j.trac.2020.116152","article-title":"Solid-state NMR spectroscopy in pharmaceutical sciences","volume":"135","author":"Li","year":"2021","journal-title":"TrAC Trends Anal. Chem."},{"key":"10.1016\/j.jpba.2024.116038_bib165","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1021\/acs.chemrev.2c00197","article-title":"Ultrafast magic angle spinning solid-state NMR spectroscopy: advances in methodology and applications","volume":"123","author":"Nishiyama","year":"2023","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jpba.2024.116038_bib166","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1021\/mp500539g","article-title":"Investigating albendazole desmotropes by solid-state NMR spectroscopy","volume":"12","author":"Chattah","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jpba.2024.116038_bib167","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1016\/j.xphs.2020.05.009","article-title":"Quantitative evaluation of the crystallinity of indomethacin using 1H T2 relaxation behaviors measured by time domain NMR","volume":"109","author":"Okada","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2024.116038_bib168","doi-asserted-by":"crossref","first-page":"8036","DOI":"10.1002\/anie.200702582","article-title":"Distinguishing anhydrous and hydrous forms of an active pharmaceutical ingredient in a tablet formulation using solid-state NMR spectroscopy","volume":"46","author":"Griffin","year":"2007","journal-title":"Angew. Chem. - Int. Ed."},{"key":"10.1016\/j.jpba.2024.116038_bib169","unstructured":"Council of Europe, \u30082.2.33\u3009 Nuclear Magnetic Resonance Spectrometry, in: European Pharmacopoeia 10.0, (2019) 58\u201360. \u3008https:\/\/www.webofpharma.com\/2021\/03\/ep-10-european-pharmacopoeia-10th.html\u3009 (accessed March 14, 2023)."},{"key":"10.1016\/j.jpba.2024.116038_bib170","unstructured":"United States Pharmacopeial Convention, \u30081761\u3009 Applications of Nuclear Magnetic Resonance Spectroscopy, in: United State Pharmacopeia National Formulary - USP 44 - NF 39, (2021). \u3008https:\/\/www.webofpharma.com\/2022\/01\/usp-2021-united-state-pharmacopeia-44.html\u3009 (accessed March 14, 2023)."},{"key":"10.1016\/j.jpba.2024.116038_bib171","unstructured":"Brazilian Health Regulatory Agency, \u30085.2.32\u3009Nuclear Magnetic Resonance, in: Brazilian Pharmacopoeia, 6th edition, (2019) MG5.2.32-00."},{"key":"10.1016\/j.jpba.2024.116038_bib172","doi-asserted-by":"crossref","unstructured":"The Minister of Health Labour and Welfare, 2.21 Nuclear Magnetic Resonance in: Japanese Pharmacopoeia XVII, (2021) 48\u201350. https:\/\/doi.org\/10.1007\/978-3-319-39193-9_47-1.","DOI":"10.1007\/978-3-319-39193-9_47-1"},{"key":"10.1016\/j.jpba.2024.116038_bib173","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ijpharm.2010.04.017","article-title":"Quantitation of a polymorphic mixture of an active pharmaceutical ingredient with solid state 13C CPMAS NMR spectroscopy","volume":"394","author":"Virtanen","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jpba.2024.116038_bib174","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijpharm.2011.02.030","article-title":"New perspectives of 19F MAS NMR in the characterization of amorphous forms of atorvastatin in dosage formulations","volume":"409","author":"Brus","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jpba.2024.116038_bib175","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jpba.2005.01.052","article-title":"Quantification of bambuterol hydrochloride in a formulated product using solid-state NMR","volume":"38","author":"Harris","year":"2005","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116038_bib176","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1016\/j.xphs.2017.07.014","article-title":"Assessing the detection limit of a minority solid-state form of a pharmaceutical by 1H double-quantum magic-angle spinning nuclear magnetic resonance spectroscopy","volume":"106","author":"Maruyoshi","year":"2017","journal-title":"J. Pharm. Sci."},{"issue":"13 (","key":"10.1016\/j.jpba.2024.116038_bib177","article-title":"Determination of the composition of delavirdine mesylate polymorph and pseudopolymorph mixtures using 13C CP\/MAS NMR","author":"Gao","year":"1996","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jpba.2024.116038_bib178","article-title":"Selective detection of active pharmaceutical ingredients in tablet formulations using solid-state NMR spectroscopy","volume":"106","author":"lee Hong","year":"2020","journal-title":"Solid State Nucl. Magn. Reson."},{"key":"10.1016\/j.jpba.2024.116038_bib179","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1021\/acs.molpharmaceut.9b00343","article-title":"Rapid characterization of formulated pharmaceuticals using fast MAS 1H solid-state NMR spectroscopy","volume":"16","author":"Hirsh","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jpba.2024.116038_bib180","doi-asserted-by":"crossref","DOI":"10.1021\/acs.analchem.2c02905","article-title":"Rapid quantification of pharmaceuticals via 1H solid-state NMR spectroscopy","author":"Wong","year":"2022","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2024.116038_bib181","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1016\/j.xphs.2020.06.026","article-title":"Quantifying pharmaceutical formulations from proton detected solid-state NMR under ultrafast magic angle spinning","volume":"109","author":"Li","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2024.116038_bib182","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1021\/acs.molpharmaceut.8b01122","article-title":"Understanding compression-induced amorphization of crystalline posaconazole","volume":"16","author":"Huang","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jpba.2024.116038_bib183","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0165-9936(02)01208-6","article-title":"Applications of Raman spectroscopy in pharmaceutical analysis","volume":"21","author":"Vankeirsbilck","year":"2002","journal-title":"TrAC - Trends Anal. Chem."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524000785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524000785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T21:43:21Z","timestamp":1715291001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708524000785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":183,"alternative-id":["S0731708524000785"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116038","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification and quantification techniques of polymorphic forms - A review","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116038"}}